Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Nat Med. 2011 Mar;17(3):297-303. doi: 10.1038/nm.2323.
Recent advances in genome technologies and the ensuing outpouring of genomic information related to cancer have accelerated the convergence of discovery science and clinical medicine. Successful examples of translating cancer genomics into therapeutics and diagnostics reinforce its potential to make possible personalized cancer medicine. However, the bottlenecks along the path of converting a genome discovery into a tangible clinical endpoint are numerous and formidable. In this Perspective, we emphasize the importance of establishing the biological relevance of a cancer genomic discovery in realizing its clinical potential and discuss some of the major obstacles to moving from the bench to the bedside.
近年来，基因组技术的进步以及随之而来的与癌症相关的基因组信息的大量涌现，加速了发现科学和临床医学的融合。将癌症基因组学转化为治疗和诊断方法的成功范例，强化了其实现个体化癌症医学的潜力。然而，将基因组发现转化为切实可行的临床终点的过程中存在众多且艰巨的瓶颈。在本观点中，我们强调了在实现癌症基因组发现的临床潜力过程中，确定其生物学相关性的重要性，并讨论了从实验室到临床应用所面临的一些主要障碍。
